Member Info for Chelsea11

It’s always good to hear different angles. However, I’ll go with what the Company is saying re strategic synergies.

“ Expanding market opportunities in smart sensing: by leveraging the Group's platform, IVS will have the access, expertise and resources to scale. There are clear opportunities to expand its geographic footprint and grow its IP-rich static technology offering with prospects to benefit from Vicon's dynamic sensing.”

Https://businesscloud.co.uk/news/oxford-metrics-plc-senses-value-in-8-1m-swoop/

14618 for me.

What makes you think they overpaid?

It’s been a very long wait since the sale of Yotta back in May 2022. Months of due diligence no doubt and the strategic synergies seem very transparent. An exciting acquisition imo.

Yet more exposure, this time at SITC, is excellent news. Worth keeping in mind though in terms of data / content, that the Late Breaking Abstract deadline was back on Sept 6th.

Great news and thanks Berm.

Could it be then, that Guys & St Thomas’, Southampton and Royal Free, were waiting for data readouts at a level that gave them the confidence needed, to commit everything that will be needed to begin recruitment?

Something appears to be building up nicely and a catalyst for volume of data in 2024 - aligning to statements made in todays Results RNS.

Well, I am more than happy to hold my hands up and openly admit I got it wrong about the Results publication date. I expected a suspension, so great news for the wider profile of the Company in the marketplace. Tar can stick, even when not at fault.

Now I’m thinking about whether the next big inflection point could perhaps be after early April 24, to provide an opportunity to whack a further £20k in my ISA!

Lots to look forward to but as always here, patience and belief will be required.

Looks like that was written by a 9 year old schoolboy.

One for the garbage.

Dragon - don't get your point.

If you're referring to the performance of the ALTYN SP after the suspension was lifted, that could be for a myriad of reasons and given that they are unrelated to Scancell, what would be the relevance here??

Suggest look back at 2022 Results RNS to see possible content / format of this years, rather than relying on the experts here. Whenever it finally arrives of course.

https://www.lse.co.uk/rns/SCLP/results-for-the-year-ended-30-april-2022-yetdif6auz7s3iq.html

Yep. No point leaving ones head jammed in the sand ;-)

I really, really hope I’m wrong but I’m expecting a trading suspension under AIM Rule 19 here next week. The 6 months is up tomorrow isn’t it?

Unpopular perhaps. Realistic I suggest.

Or a cardboard cut-out :-)

We know from the RNS on 19/09 that Scancell HAVE SUBMITTED an amendment to the current SCOPE trial protocol, to the MHRA.

“An amendment to the current trial protocol, to include a new parallel cohort with the double CPIs with iSCIB1+, has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA). iSCIB1+ has a number of additional competitive advantages to SCIB1, including potentially increased potency due to modifications to the product using Scancell's propriety AvidiMab® platform, and an extended patent life. iSCIB1+ is also able to be used by a broader patient population because it incorporates more melanoma-specific epitopes. It is anticipated that data from this cohort will read out in the first half of 2024.”

So from that we know it was submitted at least 6 weeks ago this coming Tuesday.

Making an assumption that there isn’t too much back and forth ( reasonable I think given the known status of the current SCOPE trial), I’d hope to hear news on that in November. The information at the link below would seem to back those thoughts up.

https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk#:~:text=MHRA%20acceptance%20of%20an%20application,criterion%20is%20not%20suitably%20met%20.

HAGW

High stakes here.

You’d be cross to sell and miss out.

Investing here gives you squid marks

Https://www.proactiveinvestors.com/companies/news/1030901/oxford-metrics-shares-zoom-higher-as-strong-performance-sensed-1030901.html

Revenue & PBT market expectations eclipsed.

Bolt on “ The Group finished the year with a robust cash position of £64.8m and no debt.”

Strong order book going into new financial year.

Back to £1+ in near term very likely.

Sorry but you cannot be “sure” Scancell are at ESMO, without being able to produce something to back that statement up. Without it, you are simply guessing.

Agree Violin. They may well have one or more reps at the event. Don't think though, that it should be assumed and indicated that they are there - without evidence.

However, I'd hope that becomes a moot point pretty quickly, when overtaken by trial / deal news from the Company.